Ознакомительная версия. Доступно 28 страниц из 137
Nelson-Rees W. A., Flandermeyer R. R. Inter- and intraspecies contamination of human breast tumor cell lines HBC and BrCa5 and other cell cultures // Science. 1977. March 25. Vol. 195. № 4284. P. 1343–1344.
Lucey B. P., Nelson-Rees W. A., Hutchins G. M. Henrietta Lacks, HeLa cells, and cell culture contamination // The Archives of Pathology & Laboratory Medicine. 2009. Vol. 133. № 9. P. 1463–1467.
Neimark J. Line of attack. Christopher Korch is adding up the costs of contaminated cell lines // Science. 2015. February 27. Vol. 347. № 6225. P. 938–940.
Travis K. For phase I studies, ethical and practical concerns abound // Journal of the National Cancer Institute. 2004. September 15. Vol. 96. № 18. P. 1354–1355.
Romm C. The life of a professional guinea pig // The Atlantic. 2015. September 23.
Lemmens T., Elliott C. Justice for the Professional Guinea Pig // The American Journal of Bioethics. 2001. Vol. 1. № 2. P. 51–53.
Philippidis A. Unlucky 13: top clinical trial failures of 2017 // GEN. 2018. January 3.
Boolell M., Allen M. J., Ballard S. A., Gepi-Attee S., Muirhead G. J. et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction // International Journal of Impotence Research. 1996. June 1. Vol. 8. № 2. P. 47–52.
Couzin-Frankel J. Hope in a mouse // Science. 2014. October 03. Vol. 346. № 6205. P. 28–29.
Benjamin D. J., Berger J. O., Johnson V. E. Redefine statistical significance // Nature Human Behaviour. 2018. Vol. 2. № 1. P. 6–10.
Ioannidis J. P. A. Why most published research findings are false // PLoS Medicine. 2005. August 30. Vol. 2. № 8, e124.
Lakens D., Adolfi F. G., Albers C. J., Anvari F., Apps M. A. et al. Justify Your Alpha // Nature Human Behaviour. 2018. March 1. Vol. 2. № 3. P. 168–171.
Рубанович А. В. Пересмотр критического уровня значимости (0.005 вместо 0.05): байесовский след // Радиационная биология. Радиоэкология. 2018. Т. 58. № 5. C. 453–463.
Head M. L., Holman L., Lanfear R., Kahn A. T., Jennions M. D. The extent and consequences of p-hacking in science // PLoS Biology. 2015. Vol. 13. № 3, e1002106.
Jager L. R., Leek J. T. An estimate of the science-wise false discovery rate and application to the top medical literature // Biostatistics. 2014. January 1. Vol. 15. № 1. P. 1–12.
Геппе Н. А., Фарбер И. М., Озерская И. В., Малявина У. С., Малышев В. С., Бухаров Д. Г. Использование препарата Коризалия у детей с острым инфекционным и персистирующим аллергическим ринитом // Доктор. Ру. 2017. № 4 (133). С. 54–60.
Petrov A., Perekhvatova N., Skulachev M., Stein L., Ousler G. SkQ1 ophthalmic solution for dry eye treatment: results of a phase 2 safety and efficacy clinical study in the environment and during challenge in the controlled adverse environment model // Advances in therapy. 2016. Vol. 33. № 1. P. 96–115.
Clinical trials often unregistered, unpublished // JAMA. 2017. September 11.
Chopra S. S. Industry funding of clinical trials: benefit or bias? // JAMA. 2003. Vol. 290. № 1. P. 113–114.
Als-Nielsen B., Chen W., Gluud C., Kjaergard L. L. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? // JAMA. 2003. August 20. Vol. 290. № 7. P. 921–928.
Lundh A., Lexchin J., Mintzes B., Schroll J. B., Bero L. Industry sponsorship and research outcome // Cochrane Systematic Review – Methodology. 2017. February 16.
Ioannidis J. P. A. Why most clinical research is not useful // PLoS Medicine. 2016. June 21. Vol. 13. № 6, e1002049.
Macleod M. R., Michie S., Roberts I., Dirnagl U., Chalmers I., Ioannidis J. P A. et al. Biomedical research: increasing value, reducing waste // Lancet. 2014. January 11. Vol. 383. № 9912. P. 101–104.
Ioannidis J. P. A., Greenland S., Hlatky M. A., Khoury M. J, Macleod M. R. et al. Increasing value and reducing waste in research design, conduct, and analysis // Lancet. 2014. January 11. Vol. 383. № 9912. P. 166–175.
Ioannidis J. P. A. Perfect study, poor evidence: interpretation of biases preceding study design // Seminars in hematology. 2008. July. Vol. 45. P. 160–166.
Jefferson T., Doshi P. Multisystem failure: the story of anti-influenza drugs // BMJ. 2014. April. Vol. 348, g2263.
Abramson J. D., Rosenberg H. G., Jewell N., Wright J. M. Should people at low risk of cardiovascular disease take a statin? // BMJ. 2013. Vol. 347, f6123.
Ioannidis J. P. A. Contradicted and initially stronger effects in highly cited clinical research // JAMA. 2005. July. Vol. 294. № 2. P. 218–228.
Djulbegovic B., Loughran T. P., Hornung C. A., Kloecker G., Efthimiadis E. N. et al. The quality of medical evidence in hematology-oncology // The American journal of medicine. 1999. February. Vol. 106. P. 198–205.
Isaakidis P., Swingler G. H., Pienaar E., Volmink J., Ioannidis J. P. Relation between burden of disease and randomised evidence in sub-Saharan Africa: survey of research // BMJ. 2002. March. Vol. 324. P. 702.
Swingler G. H., Pillay V., Pienaar E. D., Ioannidis J. P. International collaboration, funding and association with burden of disease in randomized controlled trials in Africa // Bulletin of the World Health Organization. 2005. July. Vol. 83. P. 511–517.
Goldberg N. H., Schneeweiss S., Kowal M. K., Gagne J. J. Availability of Comparative Efficacy Data at the Time of Drug Approval in the United States // JAMA. 2011. May. Vol. 305. № 17. P. 1786–1789.
Van Luijn J. C., Van Loenen A. C., Gribnau F. W., Leufkens H. G. Choice of comparator in active control trials of new drugs // Annals of Pharmacotherapy. 2008. November. Vol. 42. № 11. P. 1605–1612.
Safer. D. J. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials // The Journal of nervous and mental disease. 2002. September. Vol. 190. №. 9. P. 583–592.
Lapierre Y. D., Nair N. P., Chouinard G., Awad A. G., Saxena B., Jones B. et al. A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia – a Canadian multicentre trial // Acta psychiatrica Scandinavica. 1990. April. Vol. 82. P. 72–77.
Patris M., Agussol P., Alby J. M., Brion S., Burnat G., Castelnau D. et al. A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol // Acta psychiatrica Scandinavica. 1990. April. Vol. 82. P. 78–82.
Ioannidis J. P. A. More than a billion people taking statins? Potential implications of the new cardiovascular guidelines // JAMA. 2014. February 5. Vol. 311. № 5. Р. 463–464.
Ознакомительная версия. Доступно 28 страниц из 137
